<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777725</url>
  </required_header>
  <id_info>
    <org_study_id>CP-04/08</org_study_id>
    <nct_id>NCT00777725</nct_id>
  </id_info>
  <brief_title>Non-invasive Assessment of Liver Stiffness/Fibrosis by Transient Elastography (Fibroscan) in Patients With Left and/or Right Sided Heart Failure</brief_title>
  <official_title>Non-invasive Assessment of Liver Stiffness/Fibrosis by Transient Elastography (Fibroscan) in Patients With Left and/or Right Sided Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will involve 70 patients who attend the Alfred Hospital with acute or chronic&#xD;
      heart failure as well as 30 age and gender matched control subjects. All participants will&#xD;
      have their history taking and a physical examination to detect symptoms and signs of heart&#xD;
      failure.&#xD;
&#xD;
      The main objectives are for determining the benefit and usefulness of Fibroscan (Liver scan)&#xD;
      in detecting liver stiffness (a condition caused by excess fluid build up in the liver which&#xD;
      has a negative impact on the livers ability to function properly) in heart failure patients&#xD;
      and for characterizing the incidence and severity of liver stiffness in this group of&#xD;
      patients.&#xD;
&#xD;
      After informed consent, a blood sample will be taken from all patients to assess their full&#xD;
      blood examination, glucose, lipid profiles, renal function and so on.&#xD;
&#xD;
      Then 24-48 hours after enrollment, the liver doctors will do the liver scan (Fibroscan) by&#xD;
      transient elastography. All the data are recorded and further analysis will be assessed.&#xD;
&#xD;
      In a small group of acute patients the blood tests and liver scan will be repeated just prior&#xD;
      to their discharge.&#xD;
&#xD;
      Optional Sub-study: For participants who consent to the optional sub-study another 20 ml of&#xD;
      blood for serum liver fibrotic markers will be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Utility of FibroScan in detecting liver stiffness/fibrosis in HF patients</measure>
    <time_frame>Once only</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Chronic stable left sided HF patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Control subjects with no evidence of heart disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan</intervention_name>
    <description>Liver scan, similar to an ultrasound.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for fibrotic biomarkers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute and chronic heart failure patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females.&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. Confirmed written informed consent.&#xD;
&#xD;
          4. Patients/subjects are divided into 4 groups (total 100 patients/subjects).&#xD;
&#xD;
        Group 1: Chronic stable left sided HF patients who attend the Alfred Hospital. (30&#xD;
        patients)&#xD;
&#xD;
          -  Chronic stable left sided HF cohort defined as:&#xD;
&#xD;
          -  Echocardiographic evidence of systolic or diastolic heart failure (see appendix A for&#xD;
             criteria)&#xD;
&#xD;
          -  CHF patients in Class I or class II NYHA symptoms who used to have a minimum of one&#xD;
             acute decompensated episode in the past and now their clinical is stable.&#xD;
&#xD;
        Group 2: Predominant right sided HF patients secondary to valvular heart disease, pulmonary&#xD;
        artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic&#xD;
        disease and etc. (30 patients)&#xD;
&#xD;
        Group 3: Acute decompensated left sided HF patients who have volume overload and have been&#xD;
        admitted for diuresis. (10 patients)&#xD;
&#xD;
          -  Acute decompensated left sided HF cohort defined as:&#xD;
&#xD;
          -  Objective evidence of left sided heart failure (of any cause/etiology) demonstrated by&#xD;
             typical symptoms/signs combined with an imaging modality (see appendix A for criteria)&#xD;
&#xD;
          -  Requirement for intravenous diuretic whilst either an inpatient or in an emergency&#xD;
             room setting with intravenous diuretics, vasodilators or inotropes&#xD;
&#xD;
          -  No ejection fraction cut-off will be required, i.e. both systolic and diastolic heart&#xD;
             failure patients can be enrolled&#xD;
&#xD;
        Group 4: Control group: age and gender matched with no history of heart disease, no history&#xD;
        of heavy alcoholic consumption, no known history of familial hyperlipidemia, no history of&#xD;
        viral hepatitis and body mass index (BMI) less than 27. (30 subjects)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of a psychological illness or condition such as to interfere&#xD;
             with the patient's ability to understand the requirements of the study&#xD;
&#xD;
          2. History of alcoholism or current alcohol intake &gt; 4 standard drinks/day&#xD;
&#xD;
          3. Known chronic liver disease of etiology other than heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pornwalee Porapakkham, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Pornwalee Porapakkham</name_title>
    <organization>Monash University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dextrocardia</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

